Sanofi-Aventis Picks Two U.S. Heads: Rothwell, Soriot On Management Cmte.
This article was originally published in The Tan Sheet
Executive Summary
Sanofi-Aventis' U.S. business will be overseen by Sanofi U.S. CEO Tim Rothwell and Aventis U.S. Pharmaceutical Operations Head Pascal Soriot under a draft structure of the company's management team
You may also be interested in...
Sanofi-Aventis offer
Sanofi-Synthelabo extends its offer for Aventis U.S. shareholders to exchange their shares for Sanofi stock until June 30, Sanofi announces. The original deadline of May 28 was extended pending a decision by the French stock market regulator Autrite des Marches Financiers to set an expiration date. Sanofi has articulated a desire to close the $65 bil. merger in the second quarter. The firm also is awaiting final clearance from the Federal Trade Commission. Aventis accepted Sanofi's offer April 25 (1"The Tan Sheet" May 3, 2004, p. 8)...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands